Bill Wilson, MD: GLP-1 Drugs Reverse Insulin Resistance—The Master Switch to Fight Chronic Disease @Emerypharma
Bill Wilson, MD: GLP-1 Drugs Reverse Insulin Resistance—The Master Switch to Fight Chronic Disease  @Emerypharma
Uploaded March 2025 | Updated September 2026, 2 weeks ago
Dear subscribers,

In this series of shorts, we highlight key insights from conversations between Dr. Ron Najafi, CEO of Emery Pharma, and Dr. Bill Wilson, author of Brain Drain and the scientist who coined the term Carb Syndrome. Dr. Wilson’s research explores the link between high carbohydrate consumption and mental disorders.

Their discussion delves into GLP-1 agonist receptors, receptor agonists, and GIPs, examining their roles in weight loss, diabetes management, and potential muscle wasting. They also explore the risks and benefits associated with these treatments.

The full video is attached below:
youtu.be/LqtPPUom2YI

To access the curated playlist of all Professor Lustig’s talks at Emery Pharma, click here: youtube.com/playlist?list=PLlTSLi3qD78edU0aWyV8x9yLMIS-FC2fv.



About Emery Pharma:
Emery Pharma is deeply committed to advancing public health and exclusively focuses on projects that enhance the well-being of both individuals and the environment. As a comprehensive contract research laboratory, Emery Pharma provides extensive support across the entire spectrum of pharmaceutical development, covering small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.

Emery Pharma's array of premium services includes analytical and bioanalytical solutions, microbiology and cell biology services, drug and impurity characterization, and comprehensive R&D with cGMP/GLP support. The Emery Pharma team excels in customizing innovative solutions tailored to the unique requirements of each client. They seamlessly oversee the entire process, from initial drug discovery to thorough data analysis and insights generation. Their expertise allows them to tackle scientific challenges proactively, ensuring clients avoid unnecessary setbacks.

Emery Pharma's accomplished chemists and biologists harness state-of-the-art technology, encompassing cutting-edge tools such as high-resolution mass spectrometry (Orbitrap), triple quad LC-MS/MS, GC-MS, preparative HPLC, and 400 MHz multinuclear NMR.

For further details, please don't hesitate to reach out to Emery Pharma at info@emerypharma.com or explore their website at:
emerypharma.com
Bill Wilson, MD: GLP-1 Drugs Reverse Insulin Resistance—The Master Switch to Fight Chronic DiseaseRobert Lustig: Why Insulin Sensitivity Matters More Than BMI #obesity #diabetiesPresentation at Exelixis Pharma. “Nitrosamine Challenges in Drug Development: Are You Prepared?”Bill Wilson, MD: GLP-1 Cuts Sugar Cravings—Breaking the Insulin Spike and Vicious Cycle of AddictionCelebrating Innovation, Compliance, and Collaboration-Emery Pharma at PDA West Coast’s Quality BallRobert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructoseBill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with DietRevolutionizing Antibiotic Testing: MIC, MBC & Time-Kill Assays Explained | Emery Pharma #antibioticRobert Lustig, MD Live @ the Emery Pharma Feb 13, 2026 2:30 PM PT join us on zoom see link comment:Bill Wilson, MD: GLP-1 as the Master Switch for Controlling Metabolic Syndrome and DiseaseTop Bioanalysis Questions Answered: LC-MS/MS, PK/PD, Orbitrap, ADA, NMR & More at Emery PharmaRobert Lustig: Three Hits to the Liver, Including De Novo Lipogenesis and More
Emery Pharma |

Bill Wilson, MD: GLP-1 Drugs Reverse Insulin Resistance—The Master Switch to Fight Chronic Disease

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER